Citations

Clear

949 citation(s) found for "Li, Bryan".

Neuropsychological decline up to 20 years before incident mild cognitive impairment
Caselli, Richard J. , Langlais, Blake, Dueck, Amylou C. , Chen, Yinghua , Su, Yi , Woodruff, Bryan K. , Reiman, Eric M. , Langlais, Blake T., Locke, Dona E.C. , Dueck, A. C.

Mayo Clinic

Alzheimer's & Dementia | November 28, 2019 | Volume: 16 | Issue: 3 | Pages: 512-523

10.1016/j.jalz.2019.09.085 | PMID 31787561 Get It

Abstract Introduction Some Alzheimer's disease biomarker studies found amyloid changes 20 years or more in advance of expected symptoms, while cognitive changes lagged for more than a decade, but this apparent lag might reflect the sensitivities of the biomarker and cognitive assays used. How far in advance of incident amnestic mild cognitive impairment (MCI) does cognition begin to decline? Methods Longitudinal neuropsychological study of an apolipoprotein E e4 enriched cohort of cognitively normal individuals at entry. Linear mixed models for MCI converters (n = 65) and nonconverters (n = 719) fitted for each neuropsychological measure; annual changes compared between groups before and after linear model intersections (inflection points). Results 34 of 35 cognitive measures and 9 of 18 behavioral measures declined faster post‐inflection in the MCI converters; the earliest cognitive inflection point was nearly 20 years in advance of MCI diagnosis. Discussion The preclinical duration of cognitive and behavioral changes approaches the earliest reported biomarker changes.
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
Michaelson, M. Dror , Nandagopal, Lakshminarayanan , George, Saby , Alva, Ajjai , Harrison, Michael R. , Sosman, Jeffrey A. , Bhayani, Sam B., Choueiri, Toni K. , Costello, Brian A. , Derweesh, Ithaar , Kyriakopoulos, Christos E. , LaGrange, Chad A. , Lau, Clayton, Lewis, Bryan , McCreery, Brittany, McDonald, Andrew , Mortazavi, Amir , Ponsky, Lee , Redman, Bruce G., Somer, Bradley G. , Wile, Geoffrey, Dwyer, Mary A., CGC, Hammond, Lydia J., Zuccarino-Catania, Griselda, Choueiri, Toni K , Motzer, Robert J. , Jonasch, Eric W. , Gore, John L. , Haas, Naomi B , Plimack, Elizabeth R. , Agarwal, Neeraj , Gallagher, Thomas H. , Hancock, Steven Lee , Lam, Elaine T. , Manley, Brandon J. , Pierorazio, Phillip , CGC

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 7, 2019 | Volume: 17 | Issue: 11 | Pages: 1278-1285

10.6004/jnccn.2019.0054 | PMID 31693980 Get It

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non–clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-line systemic therapy options for patients with advanced clear cell renal cell carcinoma.
O3‐09‐03: RELATIONSHIP BETWEEN MIDLIFE FACTORS AND MULTIMODAL IMAGING MEASURES OF NEUROBIOLOGICAL CAPITAL: MAYO CLINIC STUDY OF AGING
Graff‐Radford, Jonathan , Przybelski, Scott A. , Lesnick, Timothy G. , Petersen, Ronald C. , Neth, Bryan J. , Schwarz, Christopher G. , Reid, Robert I. , Senjem, Matthew L. , Mielke, Michelle M. , Jack, Clifford R. , Knopman, David S. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_17 | Pages: No page available

10.1016/j.jalz.2019.06.4674 Get It

IC‐P‐156: DIET‐RELATED ALTERATIONS IN WHITE MATTER MICROSTRUCTURE IN PARTICIPANTS AT RISK FOR AD
Kellar, Derek, Whitlow, Christopher T. , Craft, Suzanne , Lockhart, Samuel N. , Neth, Bryan J. , Jung, Youngkyoo

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_2 | Pages: No page available

10.1016/j.jalz.2019.06.4271 Get It

P3‐401: DIET‐RELATED ALTERATIONS IN WHITE MATTER MICROSTRUCTURE IN PARTICIPANTS AT RISK FOR AD
Kellar, Derek, Whitlow, Christopher T. , Craft, Suzanne , Lockhart, Samuel N. , Neth, Bryan J. , Jung, Youngkyoo

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2019.06.3435 Get It

P1‐480: APOE‐DEPENDENT VERBAL LEARNING EFFECTS IN COGNITIVELY UNIMPAIRED OLDER ADULTS
Su, Yi , Devadas, Vivek, Henslin, Bruce R. , Woodruff, Bryan K. , Dueck, Amylou C., Caselli, Richard J. , Reiman, Eric M. , Malek‐Ahmadi, Michael , Su, Yi, Locke, Dona E.C.

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_8 | Pages: No page available

10.1016/j.jalz.2019.06.1085 Get It

Right brain: Art and the restoration of identity in dementia
Neth, Bryan J. , Neth, Byran J.

Mayo Clinic

Neurology | October 15, 2019 | Volume: 93 | Issue: 16 | Pages: 719-721

10.1212/wnl.0000000000008330 | PMID 31611314 Get It

Fc-Gamma Receptor IIIa and Interferon-Gamma SNPs Do Not Predict Responsiveness of Follicular Lymphoma to Galiximab (Anti-CD80 Antibody).
Czuczman, Myron S., Leigh, Bryan R., Younes, Anas , Alkuzweny, Baha, Larocca, Anne, Cao, Xianjun, Thall, Aron D., Witzig, Thomas E. , Vose, Julie M.

Mayo Clinic

Blood | October 13, 2019 | Volume: 104 | Issue: 11 | Pages: 3292-3292

10.1182/blood.v104.11.3292.3292 Get It

Abstract CD80 is an immune costimulatory molecule expressed on the cell surface of follicular and other lymphomas. Galiximab, a macaque-human chimeric anti-CD80 monoclonal antibody, has been shown to have antitumor activity in patients with relapsed or refractory, follicular lymphoma. Preclinical work suggested antibody-dependent cellular cytotoxicity (ADCC) as a mechanism for galiximab-induced cell lysis. Single-nucleotide polymorphisms (SNPs) for high-affinity Fc gamma receptor IIIa and high interferon-gamma production have been associated with increased ADCC activity. For this report, genomic DNA from peripheral blood of clinical study patients was analyzed for Fc gamma receptor IIIa and interferon-gamma gene SNPs after PCR amplification. In addition, the frequency of interferon-gamma secreting cells in peripheral blood samples was evaluated by ELISPOT. SNP and ELISPOT results were then evaluated for correlation with clinical response (CR or PR) to galiximab and reduction in tumor burden (SPD of indicator lesions). Of 35 follicular lymphoma patients evaluable for response to galiximab, 2 CRs and 1 PR were observed; time to best response was delayed (Months 3, 9, and 12). Of 34 patients with Fc gamma receptor IIIa SNP results, 6 were homozygous for the high-affinity receptor. Of 33 pts with interferon-gamma SNP results, 4 were homozygous for the high-producing allele. None of the 3 responders were homozygous for high-affinity Fc gamma receptor IIIa or high interferon-gamma production, and the degree of tumor burden reduction was smaller in these homozygotes than in the others. In addition, pretreatment interferon-gamma ELISPOT data did not predict clinical response to galiximab or tumor burden reduction. In summary, high-affinity Fc gamma receptor IIIa and high interferon-gamma production do not predict clinical responsiveness of follicular NHL to galiximab, suggesting that ADCC may not be a primary mechanism of action for this antibody. Ongoing studies are evaluating other potential mechanisms including the immunomodulatory effects of blocking CD80.
VWF Multimer Quantitation for Assessment of Cardiac Lesion Severity and Bleeding Risk
Bryan, Justin A., Austin, Christopher , Thomas, Colleen S. , Safford, Robert E. , Blackshear, Joseph L., Chen, Dong

Mayo Clinic

Blood | October 11, 2019 | Volume: 128 | Issue: 22 | Pages: 2588-2588

10.1182/blood.v128.22.2588.2588 Get It

Abstract Introduction: Recent reports have utilized von Willebrand factor (VWF) multimerquantitation in the assessment of native cardiac lesions and prosthetic valve dysfunction. However there is no standardized method for quantitation. We compared 3 methods of assessment which utilized a normal plasma control. Methods: We analyzed 476 samples and their control plasma from 395 patients including normal subjects, patients with aortic stenosis, hypertrophic cardiomyopathy, mitral or aortic regurgitation, normal and abnormal left cardiac valve prostheses, and left ventricular assist device therapy (LVAD). VWF multimers were assessed as normal or abnormal, or as normalized (patient / normal plasma) VWF multimerratios of gel bands >15/2-15 (NMR 15) or gel bands > 10/2-10 (NMR 10). We tested whether one technique was more strongly associated with hemodynamic severity of the cardiac lesion, with a history of acquired bleeding, and compared the results to a separate test of VWF function, platelet function analyzer 15 00 (PFA). Results: Two hundred seventeen patient samples reflected normal or mildly abnormal hemodynamics, 111 moderate, and 113 severely abnormal hemodynamics. Abnormal multimers were present in only 19% of samples with normal or mildly abnormal hemodynamics compared to 79% abnormal in the presence of moderate to severe hemodynamic abnormality. The distinction between moderate and severe hemodynamic abnormality was less striking, 65% versus 88% (figure, left). Quantitative NMR values declined with increasing cardiac lesion severity (figure, middle). The two quantitative multimermethods showed similar relationships to lesion severity by ANOVA, r=0.40 (NMR 15) versus r=0.36 (NMR 10), and by Spearman correlation, r=0.68 for NMR 15, and r=0.66 for NMR 10, and PFA results were comparable (all p< 0.001). Bleeding rates were associated with NMR 15, 10 and PFA (Mann-Whitney p<0.001, figure, right). Conclusion: The dichotomous normal / abnormal VWF multimer method appears to distinguish ≥ moderate hemodynamic disruption, whereas there is a continuous relationship between hemodynamic severity and quantitative multimer methods, which may be clinically useful in circumstances in which clinical estimation of lesion severity is challenging, such as with dysfunctional prosthetic valves. Progressive loss of VWF multimersappears to be associated with bleeding, suggesting that quantitative measures may provide incremental value over the dichotomous normal / abnormal designation. Figure Figure. Disclosures Blackshear: Baxalta, Inc: Consultancy, Research Funding.